There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ANI Pharmaceuticals (ANIP – Research Report), Rani Therapeutics Holdings (RANI – Research Report) and Novavax (NVAX – Research Report) with bullish sentiments.
ANI Pharmaceuticals (ANIP)
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on ANI Pharmaceuticals today and set a price target of $73.00. The company’s shares closed last Wednesday at $54.32.
According to TipRanks.com, Livnat is a 1-star analyst with an average return of
Currently, the analyst consensus on ANI Pharmaceuticals is a Strong Buy with an average price target of $71.67.
See Insiders’ Hot Stocks on TipRanks >>
Rani Therapeutics Holdings (RANI)
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Rani Therapeutics Holdings, with a price target of $16.00. The company’s shares closed last Wednesday at $1.98, close to its 52-week low of $1.82.
According to TipRanks.com, Kapoor is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rani Therapeutics Holdings with a $20.60 average price target, implying an 881.0% upside from current levels. In a report issued on November 3, Canaccord Genuity also maintained a Buy rating on the stock with a $26.00 price target.
Novavax (NVAX)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Novavax, with a price target of $35.00. The company’s shares closed last Wednesday at $6.80, close to its 52-week low of $5.61.
According to TipRanks.com, Bernardino is a 4-star analyst with an average return of
Currently, the analyst consensus on Novavax is a Moderate Buy with an average price target of $18.33, a 154.9% upside from current levels. In a report issued on October 27, B.Riley Financial also reiterated a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ANIP:
- ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
- ANIP Earnings this Week: How Will it Perform?
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
- ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares
- ANI Pharmaceuticals: FDA approves 1-mL vial of Purified Cortrophin Gel
